drugset / Trial / NCT04184518
Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma
NaSingle-groupOpen-labelTreatment
Summary
Phase II clinical trial aimed to evaluate the efficacy of the combination of cediranib and durvalumab in patients with metastatic uveal melanoma (mUM) with biopsiable disease at first line of after failure to first line systemic or liver directed therapy.
Timeline
- Start
- 2020-05
- Primary completion
- 2021-12
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cediranib | Small molecule | 20 mg | Oral |
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |